Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.

Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS.

Clin Cancer Res. 2019 Dec 1;25(23):6916-6924. doi: 10.1158/1078-0432.CCR-19-1423. Epub 2019 Jul 30.

PMID:
31363002
2.

MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM.

J Pathol. 2018 Jan;244(1):11-24. doi: 10.1002/path.4980. Epub 2017 Nov 14.

3.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24. Review.

4.

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR; Biomarkers Task Force of the NCI Investigational Drug Steering Committee.

Clin Cancer Res. 2010 Mar 15;16(6):1745-55. doi: 10.1158/1078-0432.CCR-09-2167. Epub 2010 Mar 9.

5.

Tissue-based research in kidney cancer: current challenges and future directions.

Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, Tomaszewski JE, Compton CC, Hruszkewycz A, Linehan WM, Atkins MB.

Clin Cancer Res. 2008 Jun 15;14(12):3699-705. doi: 10.1158/1078-0432.CCR-07-4733. Review.

6.

Translational crossroads for biomarkers.

Bast RC Jr, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A.

Clin Cancer Res. 2005 Sep 1;11(17):6103-8. Review.

7.

Symposium on androgen action in prostate cancer.

Tindall D, Horne FM, Hruszkewycz A, Mohla S, Shuman M, Wang Z, Kantoff P.

Cancer Res. 2004 Oct 1;64(19):7178-80. No abstract available.

8.

Speciation of human microsporidia by polymerase chain reaction single-strand conformation polymorphism.

Fedorko DP, Nelson NA, Didier ES, Bertucci D, Delgado RM, Hruszkewycz AM.

Am J Trop Med Hyg. 2001 Oct;65(4):397-401.

PMID:
11693891
9.

Preprostatectomy: A clinical model to study stromal-epithelial interactions.

Lopaczynski W, Hruszkewycz AM, Lieberman R.

Urology. 2001 Apr;57(4 Suppl 1):194-9.

PMID:
11295626
10.

Telomerase activity modulation in the prevention of prostate cancer.

Kim NW, Hruszkewycz AM.

Urology. 2001 Apr;57(4 Suppl 1):148-53. Review.

PMID:
11295615
11.

Oxidative stress in chemoprevention trials.

DeWeese TL, Hruszkewycz AM, Marnett LJ.

Urology. 2001 Apr;57(4 Suppl 1):137-40.

PMID:
11295612
12.

Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays.

Wu YY, Hruszkewycz AM, Delgado RM, Yang A, Vortmeyer AO, Moon YW, Weil RJ, Zhuang Z, Remaley AT.

Clin Chim Acta. 2000 Mar;293(1-2):199-212.

PMID:
10699434
13.

p53 mutations in cyclophosphamide-associated bladder cancer.

Khan MA, Travis LB, Lynch CF, Soini Y, Hruszkewycz AM, Delgado RM, Holowaty EJ, van Leeuwen FE, Glimelius B, Stovall M, Boice JD Jr, Tarone RE, Bennett WP.

Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):397-403.

14.

Semiautomated sequence-specific mutation detection of the human K-ras oncogene using "cold" SSCP analysis.

Hruszkewycz AM, Delgado RM, Khan MA, Bennett WP.

Clin Chem. 1996 Oct;42(10):1717-9. No abstract available.

15.

DNA polymerase action on benzo[a]pyrene-DNA adducts.

Hruszkewycz AM, Canella KA, Peltonen K, Kotrappa L, Dipple A.

Carcinogenesis. 1992 Dec;13(12):2347-52.

PMID:
1473243
16.

Lipid peroxidation and mtDNA degeneration. A hypothesis.

Hruszkewycz AM.

Mutat Res. 1992 Sep;275(3-6):243-8. Review.

PMID:
1383766
17.
18.
19.

The 8-hydroxyguanine content of isolated mitochondria increases with lipid peroxidation.

Hruszkewycz AM, Bergtold DS.

Mutat Res. 1990 Jun;244(2):123-8.

PMID:
2355934
20.

Evidence for mitochondrial DNA damage by lipid peroxidation.

Hruszkewycz AM.

Biochem Biophys Res Commun. 1988 May 31;153(1):191-7.

PMID:
2837198
21.

Oxygen radicals, lipid peroxidation and DNA damage in mitochondria.

Hruszkewycz AM, Bergtold DS.

Basic Life Sci. 1988;49:449-56. Review. No abstract available.

PMID:
3074785
22.

Destruction of microsomal cytochrome P-450 and glucose-6-phosphatase by lipids extracted from peroxidized microsomes.

Hruszkewycz AM, Glende EA Jr, Recknagel RO.

Toxicol Appl Pharmacol. 1978 Dec;46(3):695-702. No abstract available.

PMID:
218322
23.

Critical role of lipid peroxidation in carbon tetrachloride-induced loss of aminopyrine demethylase, cytochrome P-450 and glucose 6-phosphatase.

Glende EA Jr, Hruszkewycz AM, Recknagel RO.

Biochem Pharmacol. 1976 Oct 1;25(19):2163-70. No abstract available.

PMID:
9947
24.

Absolute dependence of CCL4 induced loss of glucose-6-phosphatase and cytochrome P-450 on lipid peroxidation.

Recknagel RO, Hruszkewycz AM, Glende EA Jr.

Panminerva Med. 1976 Sep-Oct;18(9-10):375-80. No abstract available.

PMID:
185572

Supplemental Content

Loading ...
Support Center